Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase I clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with Second Genome, Inc.; United Therapeutics Corporation; Everest Medicines Limited; Beacon Discovery; Boehringer Ingelheim International GmbH; Eisai Co., Ltd.; Eisai Inc.; and Aristea Therapeutics, Inc. for the development of RIST4721 for treatment of serious immune-mediated inflammatory diseases. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah.
IPO Year: 2000
Exchange: NASDAQ
Website: arenapharm.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/9/2022 | $120.00 → $100.00 | Buy → Neutral | HC Wainwright & Co. |
| 12/21/2021 | $93.00 → $100.00 | Overweight → Neutral | Cantor Fitzgerald |
| 12/14/2021 | Market Outperform → Market Perform | JMP Securities | |
| 12/14/2021 | $112.00 → $100.00 | Outperform → Market Perform | SVB Leerink |
| 12/14/2021 | $76.00 → $100.00 | Outperform → Sector Perform | RBC Capital |
| 12/14/2021 | $98.00 → $100.00 | Outperform → Neutral | Credit Suisse |
| 12/14/2021 | $100.00 | Buy → Hold | Jefferies |
| 12/13/2021 | Buy → Hold | Needham | |
| 12/8/2021 | $71.00 | Overweight | Wells Fargo |
| 8/10/2021 | $100.00 → $93.00 | Overweight | Cantor Fitzgerald |
SC 13G/A - ARENA PHARMACEUTICALS INC (0001080709) (Subject)
SC 13G/A - ARENA PHARMACEUTICALS INC (0001080709) (Subject)
SC 13G/A - ARENA PHARMACEUTICALS INC (0001080709) (Subject)
SC 13G - ARENA PHARMACEUTICALS INC (0001080709) (Subject)
SC 13G/A - ARENA PHARMACEUTICALS INC (0001080709) (Subject)
15-12G - ARENA PHARMACEUTICALS INC (0001080709) (Filer)
EFFECT - ARENA PHARMACEUTICALS INC (0001080709) (Filer)
EFFECT - ARENA PHARMACEUTICALS INC (0001080709) (Filer)
EFFECT - ARENA PHARMACEUTICALS INC (0001080709) (Filer)
EFFECT - ARENA PHARMACEUTICALS INC (0001080709) (Filer)
POSASR - ARENA PHARMACEUTICALS INC (0001080709) (Filer)
POS AM - ARENA PHARMACEUTICALS INC (0001080709) (Filer)
POS AM - ARENA PHARMACEUTICALS INC (0001080709) (Filer)
POS AM - ARENA PHARMACEUTICALS INC (0001080709) (Filer)
POS AM - ARENA PHARMACEUTICALS INC (0001080709) (Filer)
Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the appointment of Amit Munshi, as Sensorion's independent director and Chairman of the Board, effective April 1, 2025. Mr. Munshi succeeds Mr. John Furey who stepped down as an Independent Board Member. Mr. Munshi is then appointed Chairman of the Board, replacing Khalil Barrage who served as the Company's interim Chairman since March 31, 2023. Mr. Barrage will continue to serve as a director on Sensorion's Board. This appointment by the Board of directors is performed b
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced the appointment of Douglas J. Manion, M.D., F.R.C.P. (C), as Executive Vice President of Research & Development, reporting to Amit D. Munshi, President and CEO of Arena. Dr. Manion brings more than 20 years of pharmaceutical industry experience spanning three large companies, including work in all of Arena's therapeutic areas. "We are excited to have Dr. Manion join the Arena team," said Mr. Munshi. "Doug has leadership experience across all aspects of research and development, as well as extensive international experience, which will guide Arena R&D as we continue to grow and progress our portfolio." "I was attracted by the breadt
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced the appointment of Steven Schoch to the Company's Board of Directors and as Chair of the Audit Committee. Mr. Schoch brings more than 20 years of financial and operational leadership and expertise across a range of areas in biopharmaceuticals, media, and technology, including building and scaling businesses and leading innovation. "We are very pleased to have Mr. Schoch join our Board of Directors," said Garry Neil, M.D., Chair of the Board of Directors of Arena. "Steven brings both financial and strategic operational experience that will be of great benefit as Arena prepares for the next stage of growth." Mr. Schoch currently serv
SAN DIEGO--(BUSINESS WIRE)--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced changes to the Company’s Board of Directors. Garry Neil, MD, has been appointed Chair of the Board. Additionally, Nawal Ouzren has been appointed as a new Board member. “These changes in our Board leadership will help position Arena for the growth we anticipate and mark an important inflection point in our progress,” said Amit D. Munshi, President and CEO of Arena. “Garry Neil has served on the Board for the past four years, providing exceptional leadership for our scientific direction. As a physician with extensive industry experience, his insight into successfully translating scientific disco
HC Wainwright & Co. downgraded Arena Pharmaceuticals from Buy to Neutral and set a new price target of $100.00 from $120.00 previously
Cantor Fitzgerald downgraded Arena Pharmaceuticals from Overweight to Neutral and set a new price target of $100.00 from $93.00 previously
JMP Securities downgraded Arena Pharmaceuticals from Market Outperform to Market Perform
SVB Leerink downgraded Arena Pharmaceuticals from Outperform to Market Perform and set a new price target of $100.00 from $112.00 previously
RBC Capital downgraded Arena Pharmaceuticals from Outperform to Sector Perform and set a new price target of $100.00 from $76.00 previously
Credit Suisse downgraded Arena Pharmaceuticals from Outperform to Neutral and set a new price target of $100.00 from $98.00 previously
Jefferies downgraded Arena Pharmaceuticals from Buy to Hold and set a new price target of $100.00
Needham downgraded Arena Pharmaceuticals from Buy to Hold
Wells Fargo initiated coverage of Arena Pharm with a rating of Overweight and set a new price target of $71.00
Cantor Fitzgerald reiterated coverage of Arena Pharmaceuticals with a rating of Overweight and set a new price target of $93.00 from $100.00 previously
Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the appointment of Amit Munshi, as Sensorion's independent director and Chairman of the Board, effective April 1, 2025. Mr. Munshi succeeds Mr. John Furey who stepped down as an Independent Board Member. Mr. Munshi is then appointed Chairman of the Board, replacing Khalil Barrage who served as the Company's interim Chairman since March 31, 2023. Mr. Barrage will continue to serve as a director on Sensorion's Board. This appointment by the Board of directors is performed b
– Phase 3 ELEVATE UC 52 and 12 on course for Q1 2022 topline data readout Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2021. Key Program & Corporate Updates In December announced that Pfizer Inc. and Arena entered into a definitive agreement under which Pfizer has agreed to acquire Arena In November achieved target enrollment for Study A in the Phase 2/3 CULTIVATE trial for etrasimod in Crohn's disease In November the first participant was randomized in the Phase 2 trial for temanogrel in Raynaud's phenomenon secondary to systemic sclerosis Phase 3 ELEVATE program
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that the Compensation Committee of its Board of Directors granted to 18 new employees 18,527 inducement restricted stock units ("RSUs"). The inducement RSUs have a grant date and vesting commencement date of February 15, 2022 and were granted as inducements material to the new employees entering employment with Arena in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement RSUs vest over four years, with 25% of the shares vesting on the first designated quarterly vesting date on or following the one-year anniversary of the vesting commencement date and the remaining 75% of the shares vesting in 12 substantially equal quarte
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) will release its fourth quarter and full-year 2021 financial results and provide a corporate update on Wednesday, February 23, 2022, after the close of the U.S. financial markets. About Arena Pharmaceuticals ARENA Pharmaceuticals is a team with a singular purpose – deliver important medicines to patients. In a rapidly changing global market, we work with a sense of urgency every day to understand the needs of all our stakeholders, identify bold, sometimes disruptive, ideas to get medicines to patients, and relentlessly execute until it's done. ARENA - Care More. Act Differently. Forward-Looking Statements Certain statements in this press relea
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that the Compensation Committee of its Board of Directors granted inducement restricted stock units ("RSUs") to new employees. The inducement RSUs have a grant date and vesting commencement date of January 15, 2022 and were granted as inducements material to the new employees entering employment with Arena in accordance with Nasdaq Listing Rule 5635(c)(4). These grants included: RSUs to Malcolm Crooks, Senior Vice President, Head of International, at an amount of 15,111 shares, approved by the Compensation Committee on January 11, 2022; and 20,218 RSUs to 21 new employees, approved by the Compensation Committee on January 11, 202
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that the Compensation Committee of its Board of Directors granted to 16 new employees 28,659 inducement restricted stock units ("RSUs"). The inducement RSUs have a grant date and vesting commencement date of December 15, 2021 and were granted as inducements material to the new employees entering employment with Arena in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement RSUs vest over four years, with 25% of the shares vesting on the first designated quarterly vesting date on or following the one-year anniversary of the vesting commencement date and the remaining 75% of the shares vesting in 12 substantially equal quarte
Proposed acquisition offers potentially new, differentiated best-in-class approach to address unmet need for a broader number of patients with immuno-inflammatory diseases Expands innovative pipeline potentially enhancing growth through 2025 and beyond Transaction valued at $100 per Arena share in cash, for a total equity value of approximately $6.7 billion Pfizer to host analyst and investor call at 10am EST today with Pfizer I&I executives Pfizer Inc. (NYSE:PFE) and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical stage company developing innovative potential therapie
- Evaluating 2 mg and 3 mg etrasimod in study participants with moderate to severe Crohn's Disease (CD) - Topline data from CULTIVATE Study A on track for Q2 2022 Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that it has achieved target enrollment in Study A of the Phase 2/3 CULTIVATE trial evaluating the safety and efficacy of etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, in participants with moderate to severe Crohn's disease (CD). CULTIVATE Study A reached target enrollment of 70 study participants to assess etrasimod 2 mg and 3 mg in participants with CD. "Crohn's disease patients have an intense need for additional ther
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that the Compensation Committee of its Board of Directors granted to 23 new employees inducement stock options to purchase an aggregate of 39,400 shares of its common stock and 18,760 inducement restricted stock units ("RSUs"). The inducement stock options and RSUs have a grant date and vesting commencement date of November 15, 2021 and were granted as inducements material to the new employees entering employment with Arena in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock options are non-qualified stock options, have a seven-year term, have an exercise price of $58.85 per share, the closing price of Arena's co
– Phase 3 ELEVATE UC 52 and 12 on course for Q1 2022 topline data readout – First participant randomized in the Phase 2 trial for temanogrel in Raynaud's phenomenon secondary to systemic sclerosis – Strong liquidity position to support continued pipeline progress Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today provided a corporate update and reported financial results for the third quarter ended September 30, 2021. "During the quarter, the team continued to make significant progress across all key programs, including reaching full enrollment for the ELEVATE UC 12 program," said Amit D. Munshi, President and CEO of Arena. "ELEVATE UC 12 and ELEVATE UC 52 remain on track and we continu
4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)
4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)
4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)
4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)
4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)
4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)
4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)
4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)
4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)
4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)
– Phase 3 ELEVATE UC 52 and 12 on course for Q1 2022 topline data readout Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2021. Key Program & Corporate Updates In December announced that Pfizer Inc. and Arena entered into a definitive agreement under which Pfizer has agreed to acquire Arena In November achieved target enrollment for Study A in the Phase 2/3 CULTIVATE trial for etrasimod in Crohn's disease In November the first participant was randomized in the Phase 2 trial for temanogrel in Raynaud's phenomenon secondary to systemic sclerosis Phase 3 ELEVATE program
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) will release its fourth quarter and full-year 2021 financial results and provide a corporate update on Wednesday, February 23, 2022, after the close of the U.S. financial markets. About Arena Pharmaceuticals ARENA Pharmaceuticals is a team with a singular purpose – deliver important medicines to patients. In a rapidly changing global market, we work with a sense of urgency every day to understand the needs of all our stakeholders, identify bold, sometimes disruptive, ideas to get medicines to patients, and relentlessly execute until it's done. ARENA - Care More. Act Differently. Forward-Looking Statements Certain statements in this press relea
Proposed acquisition offers potentially new, differentiated best-in-class approach to address unmet need for a broader number of patients with immuno-inflammatory diseases Expands innovative pipeline potentially enhancing growth through 2025 and beyond Transaction valued at $100 per Arena share in cash, for a total equity value of approximately $6.7 billion Pfizer to host analyst and investor call at 10am EST today with Pfizer I&I executives Pfizer Inc. (NYSE:PFE) and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical stage company developing innovative potential therapie
– Phase 3 ELEVATE UC 52 and 12 on course for Q1 2022 topline data readout – First participant randomized in the Phase 2 trial for temanogrel in Raynaud's phenomenon secondary to systemic sclerosis – Strong liquidity position to support continued pipeline progress Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today provided a corporate update and reported financial results for the third quarter ended September 30, 2021. "During the quarter, the team continued to make significant progress across all key programs, including reaching full enrollment for the ELEVATE UC 12 program," said Amit D. Munshi, President and CEO of Arena. "ELEVATE UC 12 and ELEVATE UC 52 remain on track and we continu
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) will release its third quarter 2021 financial results and provide a corporate update on Thursday, November 4, 2021, after the close of the U.S. financial markets. The Company will host a question and answer session via conference call and live webcast with the investment community the same day at 4:30 PM ET. Conference Call & Webcast Information When: Thursday, November 4, 2021, at 4:30 PM ET Webcast: Conference call will be broadcast live in listen-only mode on the company's investor relations website at https://invest.arenapharm.com/events-presentations A recording of the conference call will be archived for 30 days after the call. About Arena
– Phase 3 ELEVATE UC 12 trial reached full enrollment; topline data expected Q1 2022 with ELEVATE UC 52 – Liquidity position at ~$1.0 billion as of June 30, 2021 to support continued pipeline progress Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today provided a corporate update and reported financial results for the second quarter ended June 30, 2021. "With today's announcement of the ELEVATE UC 12 trial reaching full enrollment, we look forward to a potentially transformational data readout of ELEVATE UC 12 and ELEVATE UC 52 in the first quarter of next year. We are also pleased with our recently announced partnership with Aristea to strengthen our mid-stage immunology pipeline," said Ami
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) will release its second quarter 2021 financial results and provide a corporate update on Thursday, August 5, 2021, after the close of the U.S. financial markets. The Company will host a live webcast to discuss the results with the investment community the same day at 4:30 PM ET. Conference Call & Webcast Information When: Thursday, August 5, 2021, at 4:30 PM ET Webcast: Conference call will be broadcast live in listen-only mode on the company's investor relations website at https://invest.arenapharm.com/events-presentations. A recording of the conference call will be archived for 30 days after the call. About Arena Pharmaceuticals ARENA Pharmac
Agreement Provides Arena with Exclusive Option to Acquire Aristea and its CXCR2 Programs post-Phase 2 Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Aristea Therapeutics, Inc. today announced a strategic collaboration to advance the clinical development of RIST4721, an oral CXCR2 antagonist being developed by Aristea for the treatment of palmoplantar pustulosis (PPP) and other neutrophil-mediated diseases. Under the terms of the agreement, Arena will provide a $60 million upfront payment to Aristea and a $10 million equity investment in Aristea's Series B financing. In return, Aristea has granted Arena an exclusive option to acquire Aristea, including rights to all CXCR2 programs, upon com